Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled Phase 3 trial
Lancet 2019;394:576–86. doi: 10.1016/S0140-6736(19)30952-3
Treatment with risankizumab showed significantly greater efficacy over adalimumab in providing substantial skin clearance in patients with moderate-to-severe chronic plaque PsO. This study aimed to assess the safety and efficacy of risankizumab compared with adalimumab in an active-comparator Phase 3 trial.
Additionally, frequencies of adverse events were low for both risankizumab and adalimumab, and risankizumab safety findings were consistent with those reported in previous clinical trials.
Keywords:
